Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iovance Biotherapeutics ( (IOVA) ) has shared an update.
On August 18, 2025, Iovance Biotherapeutics announced that its product Amtagvi® (lifileucel) received approval from Health Canada for use in advanced melanoma patients who have progressed after anti-PD-1 and targeted therapies. This approval marks Iovance’s first marketing authorization outside the U.S., based on the C-144-01 trial results, and signifies a strategic step in addressing unmet needs in solid tumor cancers, with plans to authorize a Canadian treatment center soon.
The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Iovance Biotherapeutics’ overall stock score is primarily impacted by weak financial performance due to profitability and cash flow challenges. However, positive earnings call sentiment and strategic restructuring efforts provide a more optimistic outlook. Technical analysis and valuation indicate mixed signals, with short-term strength but long-term concerns. Corporate events add a positive dimension, although leadership changes introduce some uncertainty.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a commercial biotechnology company that focuses on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company aims to lead in the innovation of TIL therapies, which harness the immune system to target and destroy cancer cells, and has demonstrated promising clinical data across multiple solid tumors.
Average Trading Volume: 16,882,700
Technical Sentiment Signal: Sell
Current Market Cap: $922.7M
For an in-depth examination of IOVA stock, go to TipRanks’ Overview page.